Cargando…
Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation
AIMS: The aim of the present study was to demonstrate evidence of reduced thrombin generation at the trough plasma rivaroxaban concentration. METHODS: A single‐centre, prospective, nonrandomized, drug‐intervention, self‐controlled study was conducted in 51 anticoagulation therapy‐naïve patients with...
Autores principales: | Horinaka, Shigeo, Sugawara, Rie, Yonezawa, Yutaka, Ishimitsu, Toshihiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736851/ https://www.ncbi.nlm.nih.gov/pubmed/28888219 http://dx.doi.org/10.1111/bcp.13429 |
Ejemplares similares
-
Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
por: Feng, Yan, et al.
Publicado: (2014) -
Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects
por: Allen, Ann, et al.
Publicado: (2014) -
Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study
por: Hu, Xiao, et al.
Publicado: (2015) -
A phase I pharmacokinetics trial comparing PF‐05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis
por: Cohen, Stanley, et al.
Publicado: (2016) -
Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects
por: Namour, Florence, et al.
Publicado: (2016)